GR1803 Injection in Patients With RRMM

NCT06952075 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myleoma

Interventions

DRUG: GR1803

Sponsor

Genrix (Shanghai) Biopharmaceutical Co., Ltd.